About Us
Cocrystal Pharma, Inc. is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of hepatitis viruses, influenza viruses, and noroviruses.
Learn MoreTechnology
We utilize unique structure-based technologies and Nobel Prize winning expertise to create first- and best-in-class antiviral drugs.
Learn MoreDevelopment Programs
Our development programs include a wide variety of serious and/or chronic viral diseases including hepatitis C, influenza and norovirus.
Learn More| Program | Discovery | Preclinical | Phase 1 | Phase 2 | Phase 3 |
|---|---|---|---|---|---|
|
Hepatitis C
CC-31244 (Pan-genotypic NS5B NNI) |
Discovery Phase complete
|
Preclinical Phase complete
|
Phase 1 Phase complete
|
Phase 2 Phase in progress
|
Phase 3 Phase not started
|
|
Hepatitis C
CC-2850 (Pan-genotypic NS5B Nuc) |
Discovery Phase complete
|
Preclinical Phase in progress
|
Phase 1 Phase not started
|
Phase 2 Phase not started
|
Phase 3 Phase not started
|
|
Hepatitis C
CC-2069 (Pan-genotypic NS5A inhibitor) |
Discovery Phase complete
|
Preclinical Phase in progress
|
Phase 1 Phase not started
|
Phase 2 Phase not started
|
Phase 3 Phase not started
|
|
Influenza
CC-42344 (Influenza A PB2 Inhibitor) |
Discovery Phase complete
|
Preclinical Phase in progress
|
Phase 1 Phase not started
|
Phase 2 Phase not started
|
Phase 3 Phase not started
|
| Influenza Influenza A/B Inhibitor |
Discovery Phase in progress
|
Preclinical Phase not started
|
Phase 1 Phase not started
|
Phase 2 Phase not started
|
Phase 3 Phase not started
|
| Norovirus Noro Polymerase Inhibitor |
Discovery Phase in progress
|
Preclinical Phase not started
|
Phase 1 Phase not started
|
Phase 2 Phase not started
|
Phase 3 Phase not started
|
Latest News
Stock Data
Nasdaq:
COCP
Change
Volume
Market Cap